CD19 and acute lymphoblastic leukemia: Overall, most B-ALL patients (62% to 96%) achieved CR after anti-CD19 CAR-T therapy, although relapses were observed in a consistent percentage of patients (ranging from 22 to 53%) who initially achieved remission.